Die somatische Behandlung der unipolaren depressiven Störungen. Teil 2

HolsboerTrachsler, E; Hättenschwiler, J; Beck, J; Brand, S; Hemmeter, U; Keck, ME; Rennhard, S; Hatzinger, M; Merlo, M; Bondolfi, G; Preisig, M; Andreoli, Y Attinger; Gehret, A; Bielinski, D; Seifritz, E

doi:10.4414/smf.2010.07342

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This enzyme also affects a large number of drugs [ 25 ] including SSRIs [ 26 , 29 ], opioids [ 29 ], and in particular the bioactivation of clopidogrel [ 31 ]. However, none of the Swiss DL contained the biomarker ABCB1, although the Swiss guideline on the treatment of unipolar depressive episodes recommends to test for selected genetic variants of ABCB1 (P-Glycoprotein) in patients taking antidepressants [ 32 – 34 ].…”

Section: Discussionmentioning

confidence: 99%

Pharmacogenetic information in Swiss drug labels – a systematic analysis

et al. 2020

View full text Add to dashboard Cite

Implementation of pharmacogenetics (PGx) and individualization of drug therapy is supposed to obviate adverse drug reactions or therapy failure. Health care professionals (HCPs) use drug labels (DLs) as reliable information about drugs. We analyzed the Swiss DLs to give an overview on the currently available PGx instructions. We screened 4306 DLs applying natural language processing focusing on drug metabolism (pharmacokinetics) and we assigned PGx levels following the classification system of PharmGKB. From 5979 hits, 2564 were classified as PGx-relevant affecting 167 substances. 55% (n = 93) were classified as “actionable PGx”. Frequently, PGx information appeared in the pharmacokinetics section and in DLs of the anatomic group “nervous system”. Unstandardized wording, appearance of PGx information in different sections and unclear instructions challenge HCPs to identify and interpret PGx information and translate it into practice. HCPs need harmonization and standardization of PGx information in DLs to personalize drug therapies and tailor pharmaceutical care.

show abstract

Section: Discussionmentioning

confidence: 99%

Pharmacogenetic information in Swiss drug labels – a systematic analysis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Diese Ergebnisse wurden in mehreren Metaanalysen bestätigt [76,77]. Aufgrund dieser Evidenz sind Johanniskrautextrakte folgerichtig in die Empfehlung der Schweizerischen Gesellschaft für Angst und Depression (SGAD) [78] sowie der S3-Leitline der Deutschen Gesellschaft für Psychiatrie, Psychotherapie und Neurologie (DGPPN) [79] zur psychopharmakologischen Behandlung der unipolaren leichtbis mittelgradigen Depression aufgenommen worden. Jedoch wird der Stellenwert der Psychopharmakotherapie generell bei Patienten mit leicht-bis mittelgradig depressiven Episoden seit einigen Jahren kontrovers diskutiert [80].…”

Section: Beobachtungsstudieunclassified

Ergebnisse universitärer Forschung in der Naturheilkunde: Klinische Phytotherapie

Melzer

2017

Schweiz Z Ganzheitsmed

View full text Add to dashboard Cite

KeywordsNaturopathy · Complementary medicine · Evidence-based medicine, EBM · Clinical phytotherapy · University research · Chronic diseases · Herbal medicine Summary Results of University Research in Naturopathy: Clinical PhytotherapyThe range of university research in naturopathy/complementary medicine is shown by examples of clinical phytotherapy in patients with chronic diseases. Methods of evidence-based medicine (EBM) are turned into practice to analyze the efficacy and safety of herbal preparations as well as a rationale for the combination of extracts or for confounders in trials with herbal drugs: Due to the re-analysis of raw data according to the intention-to-treat principle, two metaanalyses showed a significant and clinically relevant reduction on the one hand of gastrointestinal symptoms in 273 patients suffering from functional dyspepsia, treated with the combination preparation STW5, and on the other hand of disease-specific mortality in 602 patients suffering from alcohol-toxic liver cirrhosis and being treated with the mono-preparation silymarin -both in comparison with placebo. Two randomized controlled trials (RCT) -one using a topical arnica gel, the other tablets of a combination of four extracts -made clear that in the former no significant inferiority could be found regarding pain reduction and hand function when compared with nonsteroidal anti-inflammatory drugs in 204 patients suffering from polyarthrosis of the finger joints. In the latter, depressive and anxious symptoms were significantly reduced in 182 patients with somatoform disorders when treated with the combination of 4 extracts (Ze 185) compared to 3 extracts or to placebo. An open trial with 1,541 outpatients suffering from unipolar mild-to-moderate depressive episodes yielded, as comparable to findings with synthetic antidepressants, a negative association with disease duration, severity as well as duration of symptoms. According to the clinical question, different methodological approaches in EBM are useful to analyze herbal extracts with respect to the above-mentioned factors. Schlüsselwörter

show abstract

Die somatische Behandlung der unipolaren depressiven Störungen. Teil 2

Cited by 2 publications

References 0 publications

Pharmacogenetic information in Swiss drug labels – a systematic analysis

Pharmacogenetic information in Swiss drug labels – a systematic analysis

Ergebnisse universitärer Forschung in der Naturheilkunde: Klinische Phytotherapie

Contact Info

Product

Resources

About